SAN FRANCISCO (AFX) -- Trinity Biotech climbed 20 percent Tuesday, its
second day of major gains since the Irish firm received U.S. clearance for its
10-minute HIV test.
On Monday, Trinity's stock surged 60 percent after the company said its Uni-Gold
Recombigen HIV test had received approval from the U.S. Food and Drug
Administration. The stock followed through with more gains Tuesday, rising $1.05
to $6.19.
